During a pandemic, people with sarcoidosis may need clear information about infection prevention, vaccination and how to access regular care. Risk depends on organ involvement, current health, medicines and the infection in question. Follow current public-health guidance and your clinician’s plan. Do not stop corticosteroids or other prescribed treatment suddenly. Seek urgent help for severe breathing difficulty or rapidly worsening symptoms.

Coronavirus and sarcoidosis

COVID-19 and sarcoidosis, willingness to be vaccinated: challenges and opportunities

Historical review: Manansala and colleagues, Frontiers in Medicine, published on 30 April 2021.

 

Sarcoidosis is an immune-mediated chronic inflammatory disorder best characterised by non-caseating granulomas found in one or more affected organs. The COVID-19 pandemic presents a challenge for clinicians caring for patients with sarcoidosis, who may be at increased risk of infection compared with the general population. Given the recent availability of COVID-19 vaccines, clinicians are expected to raise questions about their effectiveness and safety in sarcoidosis. However, studies examining vaccine safety and effectiveness in sarcoidosis are lacking. In this review, we examine the current literature on vaccination in immunocompromised populations and apply it to patients with sarcoidosis. The available literature suggests that vaccines are safe and effective in patients with autoimmune disorders and in those taking immunosuppressive medicines. We explicitly recommend administering COVID-19 vaccines to patients with sarcoidosis. We also present a clinical decision algorithm to provide guidance on vaccinating patients with sarcoidosis against COVID-19.

 

Introduction

 

Sarcoidosis is an immune-mediated chronic inflammatory disorder characterised by the formation of non-caseating granulomas in one or more affected organs. These granulomas are thought to result from a maladaptive inflammatory response to an unknown antigen in genetically susceptible individuals (1, 2). Sarcoidosis most often affects the lungs, in more than 90% of patients, potentially reducing baseline lung function. It is not surprising that respiratory failure is the leading cause of mortality in these patients (3). However, sarcoidosis can also have cardiac, neurological, dermatological and ophthalmological manifestations, among others (1, 3). The COVID-19 pandemic presents a challenge for all doctors, but especially for those caring for patients with sarcoidosis; a large proportion of these patients require immunosuppressive medicines, which may lead to an increased risk of severe and opportunistic infections compared with the general population (4).

 

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the vector responsible for COVID-19, more than 130 million cases and over 2.8 million deaths had been reported worldwide by April 2021 (5). Given the highly contagious nature of the virus, there was an urgent need to develop COVID-19 vaccines. More than 200 vaccine candidates are currently in development (5–7). In light of the emergency use authorisations issued by the US Food and Drug Administration (FDA) for several COVID-19 vaccines, we aim to clarify the unique challenges presented by COVID-19 vaccination in patients with sarcoidosis. No data are currently available on the safety and effectiveness of COVID-19 vaccination in this population. In this review, we present our own clinical approach to vaccinating patients with sarcoidosis, with the aim of providing expert recommendations to doctors and patients facing sarcoidosis.

 

COVID-19 and sarcoidosis

 

Our knowledge of the pathophysiology of COVID-19 has evolved rapidly since the start of the pandemic. SARS-CoV-2 targets the ACE2 receptor found in the nasopharynx, oropharynx and lungs through numerous viral structural spike (S) proteins. After SARS-CoV-2 infiltrates the body, it rapidly replicates and spreads and can, in some cases, cause significant organ damage (8). Although most patients with COVID-19 have asymptomatic or mild disease, a small subgroup experiences a severe presentation associated with increased mortality. Much of the morbidity and mortality observed with COVID-19 is thought to arise from a hyperactive immune response that is insufficiently regulated. This phenomenon is known as a cytokine storm and has also been observed with other types of coronavirus, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A cytokine storm can lead to severe symptoms, including acute respiratory distress syndrome (ARDS), sepsis and multiorgan failure (9).

 

The currently available literature is inconclusive as to whether patients with sarcoidosis are at increased risk of contracting COVID-19. A study by Baughman and colleagues, in which the risks and outcomes of COVID-19 in patients with sarcoidosis were assessed through self-reported questionnaires, showed an overall COVID-19 rate of 2.23%, or 22,308 cases per million, from April to July 2020. Notably, this was higher than the rate of 1,060 cases per million in the US at that time. However, a subgroup analysis comparing COVID-19 rates in patients with sarcoidosis and the general population in the same location over the same period showed a similar infection rate in both groups (10). In another cohort of 238 patients with sarcoidosis, the COVID-19 rate was 2.1% from March to April 2020 (11).

Without prospective data, it is difficult to draw firm conclusions about the risk of COVID-19 in sarcoidosis because infection rates vary considerably according to geography and the period of observation.

 

The current literature suggests that patients with sarcoidosis are at increased risk of poorer COVID-19 outcomes. In the same study by Baughman and colleagues, the hospitalisation rate among patients with sarcoidosis and COVID-19 was found to be 15.8%, with one third of those hospitalised patients requiring intensive care (10). In addition, several factors may potentially increase the risk of death from COVID-19 in sarcoidosis. Firstly, patients with pulmonary sarcoidosis may have reduced pulmonary reserve, which may increase their risk of respiratory failure after contracting COVID-19 (12). Indeed, Morgenthau and colleagues found that patients with sarcoidosis whose lung function was moderately to severely impaired had higher rates of intubation and in-hospital mortality than the general population (13). In addition, comorbidities traditionally associated with glucocorticoid use, such as hypertension, diabetes and obesity, are more common in patients with sarcoidosis and are independent risk factors for poorer COVID-19 outcomes (14, 15). There is clearly a need to protect this population from poor COVID-19 outcomes through vaccination.

 

Vaccinations in sarcoidosis

 

There are limited and conflicting data on the effectiveness of vaccination in patients with sarcoidosis. In a small case-control study involving 48 patients with sarcoidosis and 33 healthy controls, 50% of the patients with sarcoidosis failed to show an adequate antibody response to diphtheria vaccination, compared with 23% of healthy controls (16). On the other hand, Tavana and colleagues conducted a prospective study comparing 23 patients with sarcoidosis with 26 healthy controls and measured the serological response to influenza vaccination. They found that the serological response to multiple influenza antigens (H1N1, H3N2 and B) was comparable between the two groups (17). However, neither study clarified whether the patients in the sarcoidosis groups were receiving immunosuppressive medicines. Thus, the effectiveness of vaccination in sarcoidosis has not been clearly established.

 

A major concern regarding the effectiveness of vaccination in sarcoidosis is the effect of immunosuppressive medicines on mounting an adequate immune response. Of particular interest are glucocorticoids, which are the first line of treatment for sarcoidosis. Other agents include methotrexate, commonly used as a steroid-sparing alternative, and biological medicines such as TNF-alpha inhibitors and B-cell-depleting therapy, which may be needed for refractory disease (18). To provide guidance on vaccination practices in sarcoidosis, we extrapolate data from patients with rheumatoid arthritis (RA), since this question has been extensively studied in that disease.

 

A meta-analysis of 13 studies involving 886 patients with RA assessed seroprotection rates, defined as achieving antibody titres above a predetermined level, following influenza vaccination. Seroprotection rates were similar between patients with RA taking glucocorticoids and healthy controls (19). Other immunosuppressive agents have been shown to reduce seroprotection rates. In a cohort of 219 patients with RA who received influenza vaccination, patients taking methotrexate (MTX) and TNF-alpha inhibitors showed an adequate, although reduced, antibody response (20). In a randomised controlled trial, Park and colleagues found that stopping MTX for 2 weeks after vaccination resulted in a statistically significant increase in the seroprotection rate following influenza vaccination, without a relevant increase in RA flares (21). Recent studies show that patients with RA taking the B-cell-depleting agent rituximab (RTX) have a reduced antibody response to influenza vaccination (22, 23). However, Van Assen and colleagues found that patients with RA vaccinated 6 months after receiving RTX had higher antibody titres than those vaccinated less than 6 months after RTX administration. This suggests that the timing of vaccination is an important factor to consider in patients receiving immunosuppressive medicines (23). Overall, the available data in patients with RA suggest that some immunosuppressive medicines negatively affect antibody titres after vaccination, while others may not. However, the relationship between antibody titre and protection from infection is not straightforward, since a higher antibody titre does not necessarily mean a higher level of protection. Other factors, such as the neutralising activity of the antibodies produced, are important determinants of protection.

 

The European League Against Rheumatism (EULAR) offers several prominent guiding principles regarding vaccination in patients with autoimmune inflammatory diseases: (1) vaccination should take place during periods of quiescent disease, (2) vaccines should ideally be administered before planned immunosuppression and (3) non-live vaccines can be administered safely while patients are taking systemic glucocorticoids and disease-modifying antirheumatic drugs (24). Regarding safety, the literature to date suggests that vaccinating patients with autoimmune inflammatory disease with non-live vaccines has not resulted in disease exacerbations. In addition, the panel found that patients did not have a significantly higher incidence of adverse effects than immunocompetent hosts (25). Given the limited data on vaccine effectiveness in sarcoidosis, Syed and colleagues extrapolated evidence from vaccination in immunosuppressed populations to propose general recommendations for vaccinating patients with sarcoidosis. In essence, they recommend administering inactivated vaccines, including pneumococcal, influenza and hepatitis B vaccines, regardless of the patient's current immunosuppressive regimen. Live attenuated vaccines should be administered before starting any biological therapy and should be avoided if the patient has already started biological treatment. It should be noted that these recommendations were supported by the World Association of Sarcoidosis and Other Granulomatous Disorders (26).

 

Challenges of COVID-19 vaccination in sarcoidosis

 

Vaccine development is a process that usually takes 10 to 15 years under normal circumstances. However, a COVID-19 vaccine received emergency use authorisation in the US from the Food and Drug Administration (FDA) on 11 December 2020, approximately 12 months after the first reported case (27). The exceptional speed of vaccine development was made possible by several factors, including knowledge of the spike protein from previous coronavirus outbreaks and its importance in eliciting neutralising antibodies, the ability to conduct several phases of clinical trials in parallel rather than sequentially, and advances in nucleic acid vaccine technologies (6, 28). More than 200 potential COVID vaccines are currently in development (7).

 

Apart from availability, the greatest challenges facing COVID-19 vaccination in sarcoidosis are safety and effectiveness. The mRNA COVID-19 vaccines, which currently have the most extensive data and are the most widely distributed, have shown exceptional effectiveness in phase III trials (95% and 94.1% for the Pfizer and Moderna vaccines, respectively) (29, 30). Phase III trials will continue for up to 2 years to establish the duration of seroprotection. It must be noted that patients with sarcoidosis and other autoimmune disorders, as well as those taking immunosuppressive medicines, were excluded from the clinical trials. Thus, at this time there are no published data on the effectiveness of mRNA vaccines in patients with sarcoidosis, given the novelty of mRNA vaccination technology. Currently, the Centers for Disease Control and Prevention (CDC) recommend administering mRNA COVID-19 vaccines to patients with autoimmune disorders or those taking immunosuppressive medicines, provided they have no other contraindications to vaccination (31).

 

Phase III trials show a favourable safety profile for both mRNA COVID-19 vaccines, characterised mainly by short-lived, mild to moderate injection-site pain, fatigue and headache. Serious systemic adverse effects were rare for both vaccines and mainly included fever, fatigue, myalgia and arthralgia (29, 30). The phase III trials are planned to continue for a total of 2 years to keep monitoring adverse effects. Of particular importance in sarcoidosis is the concern about disease flares after vaccination. Encouragingly, a previous influenza vaccination study in a small sample of patients with sarcoidosis observed no disease flares either immediately after vaccination or during a 6-month follow-up period (17). However, close monitoring of patients with sarcoidosis will be vital to observe whether COVID-19 vaccination can potentially trigger a disease flare.

 

Another safety concern with new vaccines is a phenomenon known as vaccine-associated enhanced disease (VAED), in which the immune response to a vaccine may be causally associated with more severe adverse outcomes after infection than infection without prior vaccination. This phenomenon has rarely been encountered with existing vaccines or viral infections, but it should be kept in mind with any new vaccine (7). The phase III trial data from both vaccine studies are reassuring, since severe cases of COVID-19, defined as confirmed COVID-19 with severe systemic illness including respiratory failure, shock or other forms of end-organ damage, were rare in the experimental groups (29, 30).

 

Faced with these challenges, it is recommended to follow the current CDC recommendations and the recent American College of Rheumatology (ACR) guidance for vaccinating patients with rheumatic diseases in the absence of any contraindications (31, 32). As an overarching principle, vaccination should be administered before planned immunosuppression if clinically possible. Adjustments to immunosuppressive therapy to optimise the response to vaccination should be made only during periods of well-controlled disease. There are limited data on the optimal adjustment of immunosuppressive therapy in patients with active or stable sarcoidosis. Furthermore, the ACR recommends that, regardless of disease activity and severity, except in the case of life-threatening disease, COVID-19 vaccination should take place as soon as possible (32). Here we propose an algorithm to provide guidance to clinicians on COVID-19 vaccination in patients with sarcoidosis (Figure 1). At present, this algorithm applies only to two-dose COVID-19 vaccine series. It should be noted in particular that our current algorithm does not recommend adjustments to anti-TNF-alpha therapy. However, recent data have emerged showing that the antibody response to SARS-CoV-2 may be attenuated in patients with inflammatory bowel disease taking infliximab (33). It is currently unknown whether this applies to patients with sarcoidosis, and recommendations may evolve as data become available. Finally, although the algorithm is based on ACR recommendations, we emphasise that the decision about vaccination and temporary adjustment of immunosuppressive regimens in sarcoidosis should be individualised for each patient after appropriate counselling and discussion of risks and benefits. Further research is needed to better understand the safety and effectiveness of different COVID-19 vaccines in patients with sarcoidosis, with or without immunosuppressive therapy.

 

FIGURE 1

www.frontiersin.org

Figure 1. Proposed clinical decision algorithm for vaccination in sarcoidosis with or without previous COVID-19 infection. The recommendations are based on ACR guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases (32). RTX, rituximab; TNF, tumour necrosis factor. *Current guidance does not recommend adjustments in patients taking anti-TNF-alpha therapy. However, recent data suggest that the antibody response to SARS-CoV-2 may be attenuated in some patients taking infliximab (33). At this time, it is unknown whether this applies to patients with sarcoidosis.

 

Opportunities

 

The COVID-19 pandemic offers unique opportunities to develop a better understanding of new vaccine technologies in patients with sarcoidosis and other diseases involving immune dysfunction; in addition to mRNA vaccines, DNA-based vaccines are currently being developed (6). We can also improve our understanding of the effect of immunosuppressive agents on antibody production and vaccine effectiveness.

 

COVID-19 may also offer valuable insights into the immune mechanisms involved in sarcoidosis: autophagy is essential for removing bacterial, viral and inorganic cellular debris. Previous studies found spontaneous formation of sarcoidosis-like granulomas in mouse models with knockout mutations involving the activation of rapamycin in macrophages, indicating a role for autophagy in the pathophysiology of sarcoidosis (34). Recent work by Calendar and colleagues has identified several mutations in genes involved in regulating autophagy in familial forms of sarcoidosis (35). Autophagy may also be important in the pathophysiology of COVID-19. It is hypothesised that coronaviruses exploit autophagy and bypass regulatory mechanisms to facilitate entry into cells (36). Microscopic examination of lung tissue from patients with COVID-19 reveals clusters of multinucleated giant cells and other inflammatory cells resembling those found in sarcoidosis (37).

Thus, Calendar and colleagues hypothesise that autophagy dysfunction in patients with sarcoidosis reduces the trafficking of viral RNA into vesicles during viral infections. It is possible that pathogenic variants of these genes that regulate autophagy may predispose some patients to severe manifestations of COVID-19 despite the absence of comorbidities (38). However, further research is needed before this can be confirmed.

 

Finally, the current pandemic may enable us to reduce health disparities in vaccine administration and willingness to be vaccinated among different populations. Compared with the rate of COVID-19-related deaths among non-Hispanic white people (mortality rate, 38/100,000), and after adjustment for age, the mortality rate relative to population size is 3.4 times higher among black people (mortality rate, 131/100,000), 3.3 times higher among Indigenous and Latino communities (mortality rate for both, 125/100,000), 2.9 times higher among Pacific Islander individuals (mortality rate, 111/100,000), and 1.3 times higher among Asian populations (mortality rate, 50/100,000) (39).

Women and minorities more often have more severe forms of sarcoidosis, yet mistrust of vaccination remains. Data confirm that minority populations are being vaccinated against COVID-19 at a significantly lower rate than white people, despite a higher mortality rate. This follows vaccination patterns seen with influenza (40). We can use this opportunity to assess the attitudes of patients with sarcoidosis towards willingness to be vaccinated. Patient-centred education has been found to increase influenza vaccination rates (41).

Patient-centred education has been found to increase influenza vaccination rates (41). For patients with sarcoidosis, more information is needed on vaccination rates, patients' willingness to receive vaccines, and the effects of race, sex and age in order to provide better patient-centred education. These data are being collected through a patient-centred online questionnaire. Patients are encouraged to complete the questionnaire at https://redcap.research.cchmc.org/surveys/?s=TJXWAK4FCJ .

 

Conclusion

 

The safety and effectiveness of COVID-19 vaccination in sarcoidosis have yet to be established. However, in light of the severity of the COVID-19 pandemic and the increased risk of severe pulmonary outcomes in sarcoidosis, we strongly recommend that patients with sarcoidosis be vaccinated against COVID-19. Previous studies have shown that vaccines are effective and safe in patients with autoimmune diseases and in those taking immunosuppressive medicines. It is important to be familiar with each patient's immunosuppressive medicines and to counsel patients on the risks and benefits of adjusting immunosuppressive regimens in preparation for COVID-19 vaccination. Since immunocompromised patients were excluded from COVID-19 vaccine trials, close surveillance must continue to confirm effectiveness and determine the safety profile in these patients (25, 32).

 

The COVID-19 pandemic offers several opportunities, particularly to advance our knowledge of immune responses to vaccination in patients taking immunosuppressants. In addition, COVID-19 offers a model that allows us to better understand molecular mechanisms that may be implicated in sarcoidosis. We must also use this opportunity to improve attitudes towards vaccination by listening to patients' concerns and, in every clinical interaction, presenting additional safety and effectiveness data to our patients, particularly those in minority populations.

 

Source: https://www.frontiersin.org/articles/10.3389/fmed.2021.672028/full

 

Rating: 0 stars, 0 votes.